177 related articles for article (PubMed ID: 27893016)
1. Highlights in Head and Neck Cancer.
Chau NG; Tishler RB; Haddad RI
JAMA Oncol; 2017 Apr; 3(4):441-442. PubMed ID: 27893016
[No Abstract] [Full Text] [Related]
2. Survivin overexpression in head and neck squamous cell carcinomas as a new therapeutic target (Review).
Frassanito MA; Saltarella I; Vinella A; Muzio LL; Pannone G; Fumarulo R; Vacca A; Mariggiò MA
Oncol Rep; 2019 May; 41(5):2615-2624. PubMed ID: 30896830
[TBL] [Abstract][Full Text] [Related]
3. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
[TBL] [Abstract][Full Text] [Related]
4. Cancer stem cell biomarkers for head and neck squamous cell carcinoma: A bioinformatic analysis.
Xiao M; Liu L; Zhang S; Yang X; Wang Y
Oncol Rep; 2018 Dec; 40(6):3843-3851. PubMed ID: 30542719
[TBL] [Abstract][Full Text] [Related]
5. Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma.
Sridharan V; Rahman RM; Huang RY; Chau NG; Lorch JH; Uppaluri R; Haddad RI; Hanna GJ; Schoenfeld JD
Oral Oncol; 2018 Oct; 85():29-34. PubMed ID: 30220316
[TBL] [Abstract][Full Text] [Related]
6. Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer.
Bozec A; Ebran N; Radosevic-Robin N; Chamorey E; Yahia HB; Marcie S; Gautier M; Penault-Llorca F; Milano G
Head Neck; 2017 Jan; 39(1):151-159. PubMed ID: 27507562
[TBL] [Abstract][Full Text] [Related]
7. How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?
Szturz P; Seiwert TY; Vermorken JB
J Clin Oncol; 2017 Jul; 35(20):2229-2231. PubMed ID: 28471725
[No Abstract] [Full Text] [Related]
8. Responses in patients receiving sequential paclitaxel post progression on PD1 inhibitors.
Sukari A; Nagasaka M; Abdallah N
Oral Oncol; 2018 May; 80():100-102. PubMed ID: 29605290
[TBL] [Abstract][Full Text] [Related]
9. Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach.
Galot R; Le Tourneau C; Guigay J; Licitra L; Tinhofer I; Kong A; Caballero C; Fortpied C; Bogaerts J; Govaerts AS; Staelens D; Raveloarivahy T; Rodegher L; Laes JF; Saada-Bouzid E; Machiels JP
Ann Oncol; 2018 Dec; 29(12):2313-2327. PubMed ID: 30307465
[TBL] [Abstract][Full Text] [Related]
10. Exceptional Response to PD-1 Blockade as First-Line Therapy in Head and Neck Squamous Cell Carcinoma.
Kumai T; Komatsuda H; Minami Y; Harabuchi Y
ORL J Otorhinolaryngol Relat Spec; 2020; 82(6):343-350. PubMed ID: 32882699
[TBL] [Abstract][Full Text] [Related]
11. Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
El Rassy E; Assi T; Bakouny Z; El Karak F; Pavlidis N; Ghosn M
Future Oncol; 2019 Mar; 15(8):909-923. PubMed ID: 30669875
[TBL] [Abstract][Full Text] [Related]
12. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
Bozec A; Peyrade F; Milano G
Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
[TBL] [Abstract][Full Text] [Related]
13. Systemic Treatment for Squamous Cell Carcinoma of the Head and Neck.
Shetty AV; Wong DJ
Otolaryngol Clin North Am; 2017 Aug; 50(4):775-782. PubMed ID: 28755705
[TBL] [Abstract][Full Text] [Related]
14. [Molecularly targeted therapy in head and neck cancer].
Le Tourneau C
Bull Cancer; 2010 Dec; 97(12):1453-66. PubMed ID: 21134823
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: Reanalysis of the ACTS-HNC study.
Kubota A; Nakatani E; Tsukahara K; Hasegawa Y; Takemura H; Terada T; Taguchi T; Nagahara K; Nakatani H; Yoshino K; Higaki Y; Iwae S; Beppu T; Hanamure Y; Tomita K; Kohno N; Kawabata K; Teramukai S; Fujii M;
PLoS One; 2018; 13(6):e0198391. PubMed ID: 29883463
[TBL] [Abstract][Full Text] [Related]
16. Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains?
Jelinek MJ; Vokes EE
J Clin Oncol; 2019 Nov; 37(31):2807-2814. PubMed ID: 31483688
[No Abstract] [Full Text] [Related]
17. Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer.
Sheth S; Weiss J
Future Oncol; 2018 Jul; 14(16):1547-1558. PubMed ID: 29464975
[TBL] [Abstract][Full Text] [Related]
18. Epacadostat Shows Value in Two SCCHN Trials.
Cancer Discov; 2017 Sep; 7(9):OF2. PubMed ID: 28760910
[TBL] [Abstract][Full Text] [Related]
19. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
Machiels JP; Schmitz S
Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545
[TBL] [Abstract][Full Text] [Related]
20. Locally advanced head and neck squamous cell carcinoma and melanoma simultaneously treated with pembrolizumab: an unusual situation.
Mora-Fernández V; Boada A; Manzano JL; Jaka A; Ferrándiz C
Eur J Dermatol; 2020 Dec; 30(6):743-744. PubMed ID: 33237032
[No Abstract] [Full Text] [Related]
[Next] [New Search]
